How much did lipitor's revenue decline due to generics?

How much did Lipitor’s revenue fall when generics entered?

The provided information does not include any figures about how much Lipitor (atorvastatin) revenue declined specifically because of generic competition, so the size of the generics-driven decline can’t be calculated from the available sources.

What data would be needed to answer this precisely?

To quantify “how much did Lipitor’s revenue decline due to generics,” you would typically need:
- Lipitor’s revenue trends before generic entry (baseline period)
- The timing of generic launches (dates/markets)
- Revenue by quarter (or year) after generics entered
- Any adjustments for other factors (pricing changes, volume changes, mix shifts, marketing changes, or channel changes)

With only those inputs, you could estimate the generics impact as the change from baseline to the post-generic period.

If you share a source, can you compute the generics impact?

If you paste or link the numbers you have (e.g., “Lipitor revenue was $X in 20XX and $Y in 20XX after generic entry”), I can compute the absolute and percentage decline attributable to the post-generic period based on your data.

Sources

No sources were provided in the prompt.